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Abstract
Background: Chemical immobilization of Weddell seals (Leptonychotes weddellii) has previously
been, for the most part, problematic and this has been mainly attributed to the type of immobilizing
agent used. In addition to individual sensitivity, physiological status may play an important role. We
investigated the use of the intravenous administration of a 1:1 mixture of tiletamine and zolazepam
(Telazol®) to immobilize adult females at different points during a physiologically demanding 5–6
week lactation period. We also compared performance between IV and IM injection of the same
mixture.
Results: The tiletamine:zolazepam mixture administered intravenously was an effective method
for immobilization with no fatalities or pronounced apnoeas in 106 procedures; however, there
was a 25 % (one animal in four) mortality rate with intramuscular administration. Induction time
was slightly longer for females at the end of lactation (54.9 ± 2.3 seconds) than at post-parturition
(48.2 ± 2.9 seconds). In addition, the number of previous captures had a positive effect on induction
time. There was no evidence for effects due to age, condition (total body lipid), stage of lactation
or number of captures on recovery time.
Conclusion: We suggest that intravenous administration of tiletamine and zolazepam is an
effective and safe immobilizing agent for female Weddell seals. Although individual traits could not
explain variation in recovery time, we suggest careful monitoring of recovery times during
longitudinal studies (> 2 captures). We show that physiological pressures do not substantially affect
response to chemical immobilization with this mixture; however, consideration must be taken for
differences that may exist for immobilization of adult males and juveniles. Nevertheless, we
recommend a mass-specific dose of 0.50 – 0.65 mg/kg for future procedures with adult female
Weddell seals and a starting dose of 0.50 mg/kg for other age classes and other phocid seals.
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Immobilization of captive and free-ranging pinnipeds is
often required for biological studies, translocation or the
examination of sick or injured animals. However, pinni-
peds present unique problems when using chemical
immobilization agents because they have evolved specific
adaptations in their respiratory, cardiovascular and ther-
moregulatory systems enabling them to dive for extended
periods. These adaptations can exacerbate problems asso-
ciated with chemical immobilization procedures [1,2].
This physiological "dive response" is characterized by pro-
found bradycardia, shunting of blood away from periph-
eral tissues, and periods of prolonged apnoea [3] that can
be aggravated by the presence of immobilizing agents in
the blood and tissues. This may result in relatively high
concentrations of drug being transported to central
organs, particularly the brain, which also affects the level
of immobilization and recovery time [4]. The physiologi-
cal status of an animal has also been shown to have a pro-
found effect on sensitivity to immobilization and on the
ability to metabolize chemicals [5]. Furthermore, the
number of previous captures and immobilizations can
increase recovery time [6]. Therefore, knowledge of the
physiological (e.g., total body lipid) and anatomical char-
acteristics (e.g., in some species the trachea is flat and has
incomplete cartilaginous rings which may increase the
risk of respiratory obstruction), methods of administra-
tion, and species-specific response to particular drugs are
important for the effective, safe and optimal application
of chemical immobilization in free-ranging wildlife spe-
cies.
.
Intramuscular (IM) injection has been one of the most
commonly used routes for administration of immobiliz-
ing agents in pinnipeds [see ], and it is thought to be rela-
tively safe and easy compared to other methods.
Immobilization by intravenous (IV) injection has recently
become more common with some species [6-8]. Although
physical restraint is required prior to the administration of
drugs using IV methods, smaller doses and better control
of the intensity and duration of immobilization are gen-
erally achieved compared to IM injection methods. Pinni-
peds that received the same drugs by IV and IM injection
have been reported to have shorter induction and recov-
ery times and less variable responses when IV methods
were used [8-10].
Weddell seals (Leptonychotes weddellii) are deep-diving (>
500 m) predators that have been the subject of many stud-
ies requiring immobilization. Many of these studies have
reported varying responses to immobilizing agents [11-
15], and most have reported mortality rates ranging from
10 to 31 %, indicating that Weddell seals may be particu-
larly sensitive. More recently, a safe method of gas anaes-
thesia (zero mortality) of Weddell seals has been reported
by Kusagaya & Sato [16] and Bodley et al. [17] (n = 9, n =
11, respectively); however, this procedure is not always
practical for field situations due to the cumbersome
equipment required. Therefore, a reliable, safe and direct
technique of immobilization is still required for this spe-
cies.
A 1:1 mixture of tiletamine and zolazepam (available
commercially as Telazol®, Fort Dodge, Castle Hill, Aus-
tralia, or Zoletil®, Virbac, Peakhurst, Australia) has been
characterized by rapid, smooth induction, good analgesia
(unresponsive to painful stimuli), maintenance of pha-
ryngeal and laryngeal reflexes, and a smooth recovery
phase [18]. The tiletamine:zolazepam mixture has been
used successfully to immobilize a range of domestic and
wild mammals, including some pinniped species
[6,7,14,19-25]. In its experimental stage (2:1 ratio mixture
of tiletamine and zolazepam), Telazol was effective with
Weddell seals [14]; however, some complications (i.e.,
apnoea leading to death) were encountered in a later
study by Phelan & Green [12]. This may have been due to
the method of administration rather than the drug itself
(see Discussion). The 1:1 mixture of tileta-
mine:zolazepam potentially offers a safe and effective
method for immobilizing Weddell seals in the field.
In this study we investigated the use of tileta-
mine:zolazepam (Telazol®) for Weddell seals. We com-
pared performance between IV and IM injection, and
examined the relationship between age, body condition
(total body lipid, TBL) and stage of lactation on induction
and recovery time. We hypothesized that variation in
these parameters among individuals would influence
drug sequestration and recovery time and that this may be
more pronounced than at other stages in this species' life
history due to the physiological pressures and energetic
constraints of lactation [5]. In addition, we examined dif-
ferences in recovery time due to the number of previous
immobilizations. We hypothesized that recovery time
would decrease for individuals that had been chemically
immobilized previously, as has been found in other spe-
cies [6].
Results
There was a strong linear relationship between dosage
(mg/kg) and recovery time (GLM: information-theoretic
evidence ratio, ER = 3.3 × 107, per cent deviance
explained, %DE = 21.0 %). Examination of two outliers
revealed that there was nothing unusual about these indi-
viduals. Both were captured more than once and had aver-
age recovery times for the other captures. Exclusion of
these outliers improved the relationship (ER = 8.2 × 107,
%DE = 31.0 %, Fig. 1). To control for the size of the seal
and the level of immobilization, recovery times werePage 2 of 8
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'weighted recovery time'
Intravenous injection
Induction
The mean dosage of tiletamine:zolazepam injected IV was
0.60 ± 0.01 mg/kg, with an average induction time of 54.8
± 1.7 seconds (Fig. 2). Using information-theoretic
weights of evidence [26] to examine the variation in
induction time, there was no evidence that TBL or age
affected induction time (∆w+ ≤ 0 for both terms), but that
stage (of lactation) had some effect (∆w+ = 0.193), with
induction time being longer at the end of lactation (begin-
ning: 48.2 ± 2.9 seconds; end: 54.9 ± 2.3 seconds). We
examined if there was an effect of the number of previous
captures on induction time using a generalized linear
mixed-effects model (GLMM). Here, capture was the total
number of captures experienced by that female and induc-
tion was the induction time measured for the last capture.
The term stage was also included as a random effect to
account for variation due to stage of lactation (the terms
capture and stage were uncorrelated). The results revealed
that capture explained 64.4 % of the variation in induction
time (Fig. 3), indicating (via the evidence ratio) that this
model was 7.47 times more likely to explain variation in
induction time than the null model (i.e., a model with no
effect of capture). Table 1 shows average induction times
for each of the model predictors at average dose rates.
Recovery
Information-theoretic weights of evidence revealed that
none of the terms considered explained the variation in
weighted recovery times (∆w+ ≤ 0 for all terms). The
GLMM used to examine the influence of the number of
previous captures on weighted recovery time revealed that
capture only explained 21.0 % of the variance in weighted
recovery time and the evidence ratio of this model to that
of the null model was only 0.31, indicating no evidence of
an effect of capture (see Table 1 for average recovery times
for each of the model predictors).
Intramuscular injection
Only 4 females were injected intramuscularly with the
tiletamine:zolazepam mixture. Three of these were post-
partum captures and one was an end-lactation capture.
Average dosage was 0.9 ± 0.6 mg/kg, with an average
induction time of 15.3 ± 1.5 minutes. One female was
immobilized (IM) both post-parturition and at the end of
lactation. No problems were associated with her first
immobilization procedure. During her second capture at
the end of lactation, induction was fast (4 minutes), indi-
cating possible accidental intravenous injection. Regular
shallow breathing was maintained through most of the
procedure. However, after approximately 60 minutes she
experienced a prolonged apnoeic event, was unresponsive
to resuscitation procedures and subsequently died.
Discussion
Telazol administered intravenously was an effective drug
for the immobilization of Weddell seals. However, intra-
muscular administration was less successful with a longer
induction and recovery times and a 25 % (one animal in
four) mortality rate. The IM route of injection has been
previously favoured because physical restraint is often not
required so administration is easy and safe for personnel.
Nonetheless, the IM route of administration has some dis-
advantages. Accidental injection into the blubber (which
can be > 50 mm in adult Weddell seals) can lead to varia-
ble induction and recovery times. Furthermore, how
quickly the drug is absorbed into the bloodstream
depends, in part, on the blood supply to the muscle.
Blood supply increases during physical activity, which
could account for the deaths reported by Phelan & Green
[12] because they physically handled and restrained
females before injection. In this study, females were only
immobilized IM when IV injection was impossible (due
to this species' tendency to 'roll' when restrained), so indi-
viduals were physically handled and potentially agitated
similar to those in the Phelan & Green study. The single
death in this study may have resulted from the accidental
injection of a larger amount of drug into a vein. Other
Relationship between dosage and recovery timeFigure 1
Relationship between dosage and recovery time. Lin-
ear relationship between dosage (mg/kg) of tiletamine and 
zolazepam (1:1 mixture) and recovery time (min) in lactating 
Weddell seals. Arrows denote two animals (outliers) with 
extended recovery times.
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IM have also shown variable results, especially with
higher doses (Table 2), although these may have also
resulted from accidental injection IV. Taken together,
these observations suggest that the tiletamine:zolazepam
combination may have a narrow margin of safety in some
seal species when administered IM, and that IM adminis-
tration increases the risks associated with immobilization.
By contrast, IV administration may be an acceptable alter-
native.
Weddell seals appear to be more sensitive, to some extent,
than other species to drug type [11,13-15] and method of
administration. Some drugs (e.g., phencyclidine HCl and
succinylcholine chloride) that have lead to fatalities in
Weddell seals have also had variable and lethal results
with other similar-sized phocids [1]. Ketamine HCl, a
rapid acting dissociative with a similar molecular structure
to phencyclidine HCl, has also been lethal to Weddell
seals, but not to other species at similar dosages [1]. In
general, Weddell seals appear to respond to tiletamine
and zolazepam in a similar way to southern elephant
seals, but we can only speculate as to why differences
might exist for other drug types. Weddell seals live in an
extreme environment year round and their energetic
adaptations might influence their sensitivity and
response.
In this study, chemical immobilization with tiletamine
and zolazepam using the IV method was successful in all
cases. There was a small effect of stage of lactation on
induction time, with an increase of about six seconds
(12.2 %) at the end of lactation. The number of previous
captures appeared to increase induction time (although
sample size was admittedly low for animals immobilized
more than twice), suggesting a decrease in sensitivity to
the chemical when first introduced into the bloodstream,
even up to 2–3 weeks later. On the other hand, there were
no detectable effects of age, condition, stage of lactation
or number of previous captures on weighted recovery
time. The animals immobilized were under varying
degrees of physiological pressures associated with the neg-
ative energy balance of lactation [5]. It seems reasonable
that if physiological state was to affect weighted recovery
time it would be most evident in these individuals.
Previous studies on southern elephant seals have shown
an effect of age and condition on recovery time [5,6].
However, Woods et al. [5] found no significant difference
in recovery time between post-parturition and end-of-lac-
tation females, although they did find that pre-moult seals
(i.e., in better condition) had shorter recovery times. The
differences between individuals found in the Field et al.
[6] study were based on measurements of condition and
recovery times at three different haul-out periods sepa-
rated by months as opposed to weeks in our study. There-
fore, our results in combination with the findings of
Woods et al. [5] suggest that recovery time does not differ
between physiologically stressed animals within the same
state (e.g., lactation), although differences resulting from
changes in physiological status at other times (e.g., non-
moult to moult) may affect recovery times enough to be
measurable in field studies.
Although we did not find a difference in weighted recov-
ery time and number of captures, our sample size was low.
With a larger sample size and more repeated captures (up
to 5), Field et al. [6] found a positive relationship between
weighted recovery time for southern elephant seals and
the number of times an individual had been immobilized
previously. However, this relationship was not as appar-
ent up to 3 captures (as in this study), so it is possible that
we did not have the statistical power to detect a relation-
ship. Consequently, we suggest careful monitoring of
immobilization recovery times during longitudinal stud-
ies (≥ 3 captures) on Weddell seals to examine this poten-
tial relationship further.
Conclusion
The 1:1 mixture of tiletamine and zolazepam appears to
be a suitable and safe drug for intravenous immobiliza-
tion of Weddell seals. It appears that variability in recov-
ery rates generally increases with higher doses (Fig. 1)
Relationship between dosage and induction timeFigure 2
Relationship between dosage and induction time. 
Relationship between dosage (mg/kg) of tiletamine and 
zolazepam (1:1 mixture) and induction time (sec) in lactating 
Weddell seals.
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olism and elimination of tiletamine and zolazepam [21].
Taking these differences into consideration, we recom-
mend a mass-specific dose of 0.50 – 0.65 mg/kg which
gives an average recovery time of 26 minutes that should
be suitable for most procedures requiring immobilization
(e.g., deployment of dataloggers, tissue sampling, injec-
tion of isotopic compounds to examine body composi-
tion, etc.). This corresponds to the dosage recommended
for southern elephant seals by McMahon et al. [7].
Although immobilization techniques will vary for species
and situations, this suggests that a mass-specific dose of
0.50 mg/kg may be a good starting point for other age
classes and other phocid seals.
Methods
Field procedures
A total of 110 chemical immobilization procedures using
Telazol (1:1 mixture of tiletamine and zolazepam) were
done on adult female Weddell seals as part of a study on
maternal energy expenditure and lactation energetics.
One hundred and six of these were by IV injection and 4
were by IM injection. Some individuals were immobilized
more than once during the course of their lactation period
(5–6 weeks), but no individuals were immobilized more
than three times. Females were caught on the sea ice at
Erebus Bay, Antarctica (77° 51' S, 166° 45' E) during the
breeding season (October to December) of 2002 and
2003. Individuals were identified by flipper tags attached
in previous years as part of a long-term tagging study [27],
and ages ranged from 6 to 22 years old.
Females were easily approached on the ice and pups were
relocated several metres away to avoid potential injury.
Subsequently, a canvas bag was placed over the female's
head [7], after which the majority of individuals remained
in a prone position without struggle. The few that were
slightly agitated would commence a 'rolling' behaviour
and could not be restrained effectively on the ice. How-
ever, this behaviour typically ceased within 2–3 minutes.
Females were then injected with Telazol intravenously via
the extra-dural vein in the lumbar region [7] using a 5 ml
syringe and 15 cm (6") 18G spinal needle, or intramuscu-
larly in the rear flank with a 10 ml syringe and 9 cm (3.5")
18G needle. We attempted to give dosages of 0.5 mg/kg
[7] and 0.75 mg/kg [14] IV and IM, respectively. Dosages
at the first capture were calculated using an estimate of
female body weight based on researcher's previous experi-
ence working with phocids. For additional captures, dos-
ages were calculated by estimating mass loss rates through
lactation. Drug induction and recovery times were
recorded and the respiratory rate and volume of air mov-
ing (as estimated by listening to breathing sounds) were
monitored throughout procedures. Induction time (sec-
onds) was defined as the time from injection until the ani-
mal did not respond to a tap on the nose [7]. The recovery
time (minutes) was defined as the time from immobiliza-
tion until the seal responded to a tap on the nose by mov-
ing and raising its head and maintaining its head in a
raised position for ~10 seconds [28]. This was repeated
several times to ensure complete recovery. An endotra-
cheal tube, oxygen, doxapram hydrochloride (Dopram®,
Wyeth, Baulkham Hills, Australia) and flumazenil (Anex-
ate®, Roche, Castle Hill, Australia) were available in the
event of respiratory arrest.
After immobilization, females were weighed to the near-
est 1 kg using electronic scales and standard body length
and six girth measurements [G1-G6, ] were recorded. The
precise dosages of tiletamine:zolazepam were calculated
for each female based on measured weights. Body compo-
sition (i.e., proportion of lipid and lean tissues) was meas-
ured using an isotopically labelled water technique. A 10
ml blood sample was collected to measure background
isotope levels followed by the IV injection of a pre-
weighed dose (to the nearest 0.1 mg) of 222 MBq tritiated
water (HTO) into the extradural vein. The syringe was
flushed with blood twice to ensure complete isotope
delivery. A second blood sample (10 ml) was taken
approximately 150 minutes after initial injection for the
calculation of dilution space and body composition.
Induction time relative to number of capturesFig re 3
Induction time relative to number of captures. Aver-
age induction time (± 2 SE) of adult lactating Weddell seals 
immobilized with tiletamine and zolazepam (1:1 mixture). 
Induction time increased with the number of previous cap-
tures.
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BMC Veterinary Research 2006, 2:8 http://www.biomedcentral.com/1746-6148/2/8Houser & Costa [29] found that HTO equilibration occurs
within 90 minutes of an intravenous injection of northern
elephant seal (Mirounga angustirostris) pups. Equilibration
occurs in southern elephant seal (M. leonina) pups within
120 minutes of administration (IV; K.E. Wheatley, unpub-
lished data). Therefore, we considered 150 minutes to be
sufficient time before collecting a second blood sample.
All samples were stored at -20°C until analysis.
Laboratory analysis
Plasma samples were analysed for HTO activity using liq-
uid scintillation spectrometry. Plasma samples (100 µl)
were distilled in triplicate using the method of Ortiz et al.
[30]. For each vial of water recovered, 4 ml of EcoLite scin-
tillate (ICN, Costa Mesa, USA) was added and HTO activ-
ity was counted for 15 minutes using a Beckman LS6500
scintillation counter. Correction for quenching was made
by automatic external standardization. Calculations of
body composition were done as described by Reilly &
Fedak [31].
Data analysis and calculations
We did not obtain body composition data for 37 captures,
but for 11 of these animals we obtained composition data
for captures before and after the capture in question. Body
composition for this intermediate capture was estimated
by interpolation, assuming the change in composition
was linearly proportional to a change in mass.
A set of generalized linear models (GLM) and penalized
quasi-likelihood [PQL, ] generalized linear mixed-effects
models (GLMM) were constructed to examine the rela-
tionships between recovery and induction time and the
various state variables. GLMs extend the standard regres-
sion model by (1) distributing the response y about its
expected value µ according to a distribution F (e.g., nor-
mal, gamma, binomial, etc.), and (2) entering the predic-
tors x1, x2,., xm into the model through the linear predictorη, which is related to the expected response µ by a monot-
onic link function ηi = η(µi) [33]. GLMMs are linear mod-
els that include both fixed and random effects, where
Table 1: Summary of induction and recovery times at average dose rates for different physiological conditions tested
Dosage (mg/kg) Induction (sec) Recovery (min)
Range Mean SE Mean SE Mean SE
Capture 1 0.60 0.01 49.5 2.98 32.2 1.61
2 0.52 0.00 64.4 2.88 20.4 0.97
3 0.69 0.02 54.9 2.24 30.6 2.27
Age (yr) 6 – 9 0.62 0.02 48.4 1.95 29.1 1.91
10 – 14 0.60 0.02 57.5 2.84 26.9 2.07
15 + 0.57 0.02 61.3 6.07 29.7 3.20
% TBL 21 – 33 0.65 0.02 52.7 2.74 27.8 2.51
34 – 40 0.62 0.02 57.9 3.20 27.6 1.78
41 + 0.62 0.02 48.6 3.39 35.2 2.40
Table 2: Summary of dosages of tiletamine:zolazepam (1:1) used for chemically immobilizing phocid seals
Species n Dosage (mg/kg) Route Mortality % Reference
Halichoerus grypus Grey seal 44 1.0 IM dart 0 [24]
Phoca vitulina Harbour seal 7 0.75 – 2.0 IM 0 [14]
Hydrurga leptonyx Leopard 
seal
1 2.0 IM 100 [37]
Leptonychotes weddellii 
Weddell seal
30 0.67 IM 10 [12]
4 0.86 IM 25 this study
106 0.60 IV 0 this study
Mirounga leonina Southern 
elephant seal
90 1.0 IM dart 0 [24]
5 2.0 IM 40 [37]
4 0.6 – 1.7 IM 0 [19]
597 0.46 IV 0 [7]
1033 0.53 IV 0 [6]Page 6 of 8
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imental units drawn at random from a population [e.g.,
individuals as in this study, ]. GLMMs offer the advantage
of partitioning variances due to the effects under investi-
gation (fixed) and those that do not contribute to the
hypotheses being tested (random).
Model comparison used Kullback-Leibler information to
assign relative strength of evidence (Akaike's Information
Criterion corrected for small samples [AICc, 26, 35]) to
each model in the set [26]. To compare a more complex
model a to a simpler model b, we employed the informa-
tion-theoretic evidence ratio (ER = AICc weight of model a
÷ AICc weight of model b) to quantify the relative support
of a versus b, and used the per cent deviance explained
(%DE) to determine structural goodness-of-fit of model a
(test for model adequacy). Higher ER values indicate
higher likelihoods of the tested model relative to model b
(e.g., the null model).
The weights of evidence (w+i) for each predictor were cal-
culated by summing the model AICc weights (wi) over all
models in which each term appeared. However, the w+i
values are relative, not absolute because they will be > 0
even if the predictor has no contextual explanatory impor-
tance [26]. Therefore, a baseline for comparing relative
w+i across predictors is required to ascertain which predic-
tors are relevant. We randomized the data for each predic-
tor separately within the dataset, re-calculated w+i, and
repeated this procedure 100 times for each predictor. The
median of this new randomized w+i distribution for each
predictor was taken as the baseline (null) value (w+0). For
each term the relative weight of evidence (∆w+) was
obtained by subtracting w+0 from w+i. Predictors with ∆w+
of zero or less have essentially no explanatory power [26].
To account for repeated captures (measurements), a series
of GLMMs were constructed to examine relationships
between induction and weighted recovery times and the
age, total body lipid, stage of lactation and total number
of captures. Examination of the residuals for the GLMMs
determined that the gamma error distribution family and
an identity link function were the most appropriate for
each analysis. All statistical analyses were done using the
R Package [Ver. 2.0.1, ]. Values are presented as mean ±
one standard error (SE) unless otherwise stated.
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